Nimotuzumab combined with radiotherapy reduces primary tumor and nodal volume in advanced undifferentiated nasopharyngeal carcinoma

Asia-Pacific Journal of Clinical Oncology

Volumn 5, Issue 3, 2009, Pages 175-180

  Gondhowiardjo, Soehartati ^a   Muthalib, Abdul ^a   Khotimah, Siti ^a   Rachman, Andhika ^a  

^a CIPTO MANGUNKUSUMO HOSPITAL   (Indonesia)

Author keywords

Efficacy; Nasopharyngeal carcinoma; Nimotuzumab; Safety

Indexed keywords

NIMOTUZUMAB;

ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DERMATITIS; DRUG ACTIVITY; DRUG MECHANISM; FEMALE; HUMAN; HYPOTENSION; LYMPH NODE METASTASIS; MALE; NASOPHARYNX CARCINOMA; NAUSEA; PRIORITY JOURNAL; PRURITUS; STOMATITIS; UNDIFFERENTIATED CARCINOMA; VOMITING;

EID: 70350104998     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2009.01227.x     Document Type: Article

References (30)

1. Chan AT, Teo PM, Jhonson PJ. Nasopharyngeal carcinoma. Ann Oncol 2002, 13:1007-15.
2. Roychowdhury DF, Tseng AJ, Weinberg V. New prognostic factors in nasopharyngeal carcinoma: tumor angiogenesis and C-erbB2 expression. Cancer 1996, 77:1419-26.
3. Agulnik M, Siu LL. State-of-the-art management of nasopharyngeal carcinoma: current and future directions. Br J Cancer 2005, 92:799-806.
4. Zimmerman M, Zouhair A, Azria D. The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications. Radiat Oncol 2006, 1:11-16.
5. Reuter CVM, Morgan MA, Eckardt A. Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck. Br J Cancer 2007, 96:408-16.
6. Giordano A, Rustum YM, Wenner CE. Cell cycle: molecular targets for diagnosis and therapy: tumor suppressor genes and cell cycle progression in cancer. J Cell Biochem 1998, 70:1-7.
7. Prenzel N, Fischer OM, Streit S. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 2001, 8:11-31.
8. Petit AM, Rak J, Hung MC. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases downregulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997, 151:1523-30.
9. Kerbel RS, Viloria-Petit A, Okada F. Establishing a link between oncogenes and tumor angiogenesis. Mol Med 1998, 4:286-95.
10. Zhou X, Liu Y, Payne G. Growth factors inactivate the cell death promoter BAD by phosphorylation of its BH3 domain on Ser155. J Biol Chem 2000, 275:25046-51.
11. Gibson EM, Henson ES, Haney N. Epidermal growth factor protects epithelial-derived cells from tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by inhibiting cytochrome C release. Cancer Res 2002, 62:488-96.
12. Ramos TC, Parada C, Escobar I. h-R3. Drugs Future 2003, 28:847-53.
13. Grandis JR, Melhem MF, Gooding WE. Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998, 90:824-32.
14. Zheng X, Hu L, Chen F. Expression of Ki67 antigen, epidermal growth factor receptor and Epstein Barr virus encoded latent membrane protein (LMP) in nasopharyngeal carcinoma. Eur J Cancer B Oral Oncol 1994, 30B:290-5.
15. Leong JL, Loh KS, Putti TC. Epidermal growth factor receptor in undifferentiated carcinoma of the nasopharynx. Laryngoscope 2004, 114:153-7.
16. Stevenson D, Charalambous C, Wilson JB. Epstein-Barr virus latent membrane protein 1 (CAO) up-regulates VEGF and TGFA concomitant with hyperplasia, with subsequent up-regulation of p16 and MMP9. Cancer Res 2005, 65:8826-35.
17. Poon TCW, Chan ATC, To KF. Expression and prognostic factor of epidermal growth factor receptor and HER2 protein in nasopharyngeal carcinoma. Proc Am Soc Clin Oncol 2001, 20:229a. abstr 913
18. Chua DTT, Nicholls John M, Sham JST. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 2004, 59:11-20.
19. Song J, Chen C, Raben D. Emerging role of EGFR-targeted therapies and radiation in head and neck cancer. Oncology 2004, 18:1757-67.
20. Crombet T, Rak J, Perez R. Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: a humanized anti-EGFR antibody. Int J Cancer 2002, 101:567-75.
21. Crombet T, Torres L, Neninger E. Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer. J Immunother 2003, 26:139-48.
22. Crombet T, Osorio M, Cruz T. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004, 22:1646-54.
23. Suresh KM, Ilona MS, Jonas C. Clinical applications of tumor volume measurements for predicting outcome in patients with squamous cell carcinoma of the upper aerodigestive tract. AJNR Am J Neuroradiol 2004, 25:1425-32.
24. Labadie RF, Yarborough WG, Weissler MC. Nodal volume reduction after concurrent chemo- and radiotherapy: correlation between initial CT and histologic findings. AJNR Am J Neuroradiol 2000, 21:310-14.
25. Zhou JY, Chong VFH, Khoo JBK, Chan KL, Huang J. The relationship between nasopharyngeal carcinoma tumor volume and TNM T-classification: a quantitative analysis. Eur Arch Otorhinolaryngol 2007, 264:169-74.
26. Bonner JA, Harari PM, Giralt J. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567-78.
27. Mateo C, Moreno E, Amour K. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. Immunotechnology 1997, 3:71-81.
28. Chan AT, Teo PM, Ngan RK. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression free survival analysis of a phase III randomized trial. J Clin Oncol 2002, 20:2038-44.
29. Lin JC, Jan JS, Hsu CY. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 2003, 21:631-7.
30. Soler RP, Delord JP, Halpern A. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 2005, 10:345-56.